There's mixed interest in biotech, biopharmaceutical and emerging pharma companies.
Health care is in the index's top spot for first time since 1988 and looks to remain strong.
Some major branded drugs will lose patent protection, and market share along with it, this year.
This biotech behemoth's appeal is its combined value-and-growth stock characteristics.
Green Mountain is downgraded to 'neutral,' and Wells Fargo is upgraded to 'buy.'
A report questions whether the FDA will grant New Chemical Entity status for the phosphate binder.
Ford is downgraded to 'equal weight,' and Saks is initiated with a 'buy.'
VIDEO ON MSN MONEY
Copyright © 2013 Microsoft. All rights reserved.
Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.
The Fed may start tapering in just a few months. Here are a few of the likely winners and losers.
The Market Dispatches column has been discontinued. Here's where to find the latest stock and business news on MSN Money, and the latest from market writer Charley Blaine.
MONEY & POLITICS
Breaking up big banks is an untested solution to the too big to fail problem that attempts to isolate and dismantle large, troubled institutions while protecting the rest of the economy.
If you're not the paranoid type, you might be after you read this article. We break down the common holiday scams -- 20 in all.
The IRS is struggling to combat identify thieves who file fraudulent tax returns in the names of older residents who don't need to file.